2.Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration.
Joo Youn PARK ; Seung Hoon KIM ; Tae Kwann PARK ; Young Hoon OHN
Korean Journal of Ophthalmology 2011;25(3):161-165
PURPOSE: To evaluate the changes in multifocal electroretinogram (mfERG) and optical coherence tomography (OCT) after intravitreal bevacizumab injection in the treatment of age-related macular degeneration (AMD). METHODS: Twenty-one eyes with choroidal neovascularization secondary to AMD were studied before and after intravitreal bevacizumab injection for best corrected visual acuity (BCVA), OCT, and mfERG. RESULTS: The BCVA improved, while central macular thickness and total macular volume in OCT decreased after intravitreal bevacizumab injection (p = 0.03, 0.01, and 0.01, respectively). In mfERG, the amplitude of P1, and implicit time of P1 and N1 indicated a statistically significant improvement of retinal response after intravitreal bevacizumab injection. CONCLUSIONS: There is a potential role for mfERG in evaluating the effect on retinal function of intravitreal bevacizumab injection.
Adult
;
Aged
;
Angiogenesis Inhibitors/*administration & dosage
;
Antibodies, Monoclonal/*administration & dosage
;
Choroidal Neovascularization/*drug therapy/*etiology
;
Electroretinography/*methods
;
Eyeglasses
;
Humans
;
Intravitreal Injections
;
Macular Degeneration/*complications/diagnosis/physiopathology
;
Middle Aged
;
Retina/drug effects/physiopathology
;
Tomography, Optical Coherence
;
Visual Acuity
3.The Development of Recurrent Choroidal Neovascularization in a Patient with Choroidal Coloboma.
Sun Ho LEE ; Jae Kyun AHN ; Hyeong Gon YU
Korean Journal of Ophthalmology 2011;25(1):63-65
We report a case of recurrent choroidal neovascularization (CNV) in an eye with chorioretinal coloboma. A 36-year-old woman presented complaining of decreased visual acuity (VA) in her left eye. Best corrected visual acuity (BCVA) was 20/200 and iris coloboma was observed. Funduscopy and fluorescein angiography (FA) showed CNV in the superior extrafoveal region with chorioretinal coloboma reaching just inferior to the optic disc. No other cause for CNV was observed except for the chorioretinal coloboma. BCVA improved to 20/30 after laser photocoagulation. She revisited our clinic for deteriorating VA (20/400) in the same eye 3 years after treatment. Funduscopy and FA demonstrated recurrent CNV with subfoveal hemorrhage. Photodynamic therapy (PDT) was followed by three consecutive intravitreal bevacizumab injections (IVB) for the subfoveally-located CNV. However, the CNV persisted with the appearance of a fresh subretinal hemorrhage. Additional PDT was combined with IVB on the same day 6 months after the initial PDT. The CNV regressed 3 months after treatment and has not recurred as of 8 months after the last treatment. The patient's BCVA improved to 20/60. This case suggests that PDT combined with IVB can be an alternative treatment for the management of recurrent CNV after laser photocoagulation in eyes with chorioretinal coloboma.
Adult
;
Angiogenesis Inhibitors/administration & dosage
;
Antibodies, Monoclonal/administration & dosage
;
Choroid Diseases/*complications/drug therapy/surgery
;
Choroidal Neovascularization/diagnosis/*etiology/physiopathology
;
Coloboma/*complications/drug therapy/surgery
;
Female
;
Fluorescein Angiography
;
Fundus Oculi
;
Humans
;
Intravitreal Injections
;
Laser Coagulation
;
Photochemotherapy
;
Recurrence
;
Visual Acuity
4.The Anti-angiogenic Effect of Chlorogenic Acid on Choroidal Neovascularization.
Cinoo KIM ; Hyeong Gon YU ; Joonhong SOHN
Korean Journal of Ophthalmology 2010;24(3):163-168
PURPOSE: To evaluate the inhibitory effect of chlorogenic acid on laser-induced choroidal neovascularization (CNV) in a rat model. METHODS: Intraperitoneal injection of chlorogenic acid (10 mg/kg) was inititated one day prior to laser photocoagulation and continued for eight days. Eyes were removed 14 days after laser photocoagulation. Fluorescein angiography was employed at seven and 14 days to assess the CNV lesions, and histological examination was performed. Quantification of CNV size and leakage were performed both in histological sections and fluorescein angiography in order to compare the inhibitory effects of chlorogenic acid on CNV with the results of the control. RESULTS: Histological analysis showed no significant difference in CNV size between the treated and control groups. However, CNV leakage on fluorescein angiography had significantly decreased in the chlorogenic acid-treated group at 14 days after laser photocoagulation compared with that of the control group. In addition, CNV size on fluorescein angiography had significantly decreased in the treated group at seven and 14 days. CONCLUSIONS: These results suggest that chlorogenic acid has anti-angiogenic effects on CNV and may be useful as an inhibitor in the treatment or prevention of neovascular age-related macular degeneration.
Angiogenesis Inhibitors/*administration & dosage
;
Animals
;
Capillary Permeability/drug effects
;
Chlorogenic Acid/*administration & dosage
;
Choroid/pathology
;
Choroidal Neovascularization/diagnosis/etiology/*physiopathology
;
Fluorescein Angiography
;
Injections, Intraperitoneal
;
Laser Coagulation
;
Radiation Injuries
;
Rats
;
Rats, Inbred BN
5.Photodynamic Therapy Combined with Intravitreal Bevacizumab in a Patient with Choroidal Neovascularization Secondary to Choroidal Osteoma.
Jung Hyun JANG ; Keong Hwan KIM ; Soo Jung LEE ; Jung Min PARK
Korean Journal of Ophthalmology 2012;26(6):478-480
Choroidal osteoma is a benign ossified tumor that is found predominantly in healthy young women during their second and third decades of life. The lesions are white-to-cream or orange in color, are located in the peripapillary and macular areas, and are unilateral in most patients. The symptoms of choroidal osteoma include decreased visual acuity and metamorphopsia or scotoma corresponding to the location of the osteoma, but some patients have no symptoms. Prognosis of vision varies according to tumor location, retinal pigment epithelial and sensory retinal degeneration, subretinal fluid and hemorrhage, and development of a subretinal neovascular membrane.
Angiogenesis Inhibitors/administration & dosage
;
Antibodies, Monoclonal, Humanized/*administration & dosage
;
Choroid Neoplasms/*complications/diagnosis
;
Choroidal Neovascularization/diagnosis/*drug therapy/etiology
;
Female
;
Fluorescein Angiography
;
Humans
;
Intravitreal Injections
;
Middle Aged
;
Osteoma/*complications/diagnosis
;
Photochemotherapy/*methods
;
Tomography, Optical Coherence
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity
6.Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
Hyun Woong KIM ; Jung Lim KIM ; Mi Hyun LEE ; Hyung Gon YOO ; In Young CHUNG ; Ji Eun LEE
Korean Journal of Ophthalmology 2011;25(4):231-237
PURPOSE: To evaluate the outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab in choroidal neovascularization secondary to age-related macular degeneration. METHODS: Photodynamic therapy (PDT) was administered to 28 eyes followed by 3 consecutive bevacizumab injections. Patients were followed-up for more than 12 months. At baseline, 1, 3, 6, and 12 months post PDT, visual acuity (VA) and central macular thickness were measured using optical coherence tomography. RESULTS: The mean VA was significantly improved from logarithm of the minimal angle of resolution 0.86 at baseline to 0.69 at 1 month (p = 0.011), 0.63 at 3 months (p = 0.003), 0.64 at 6 months (p = 0.004) and 0.60 at 12 months (p < 0.001). Central macular thickness decreased significantly from 328.3 microm at baseline to 230.0 microm at 6 months and 229.9 microm at 1 year (p < 0.001). Reinjection mean number was 0.4 for 6 months and 0.8 for 12 months. By 1 year, retreatment was performed in 10 eyes (36%). CONCLUSIONS: PDT combined with three consecutive intraviteal bevacizumab injections was effective in improving VA and reducing central macular thickness.
Aged
;
Angiogenesis Inhibitors/*administration & dosage
;
Antibodies, Monoclonal, Humanized/*administration & dosage
;
Choroidal Neovascularization/diagnosis/*drug therapy/etiology
;
Dose-Response Relationship, Drug
;
Drug Therapy, Combination
;
Female
;
Fluorescein Angiography
;
Follow-Up Studies
;
Fundus Oculi
;
Humans
;
Intravitreal Injections
;
Macula Lutea/drug effects/*pathology
;
Macular Degeneration/*complications/diagnosis/drug therapy
;
Male
;
Photochemotherapy/*methods
;
Photosensitizing Agents/administration & dosage
;
Porphyrins/*administration & dosage
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Treatment Outcome
;
Visual Acuity
7.Time-Lag between Subretinal Fluid and Pigment Epithelial Detachment Reduction after Polypoidal Choroidal Vasculopathy Treatment.
Ju Byung CHAE ; Joo Yong LEE ; Sung Jae YANG ; June Gone KIM ; Young Hee YOON
Korean Journal of Ophthalmology 2011;25(2):98-104
PURPOSE: The goal of the present research was to study post-treatment changes in polypoidal choroidal vasculopathy (PCV) shown by optical coherence tomography (OCT). METHODS: The study included 12 patients with naive PCV. Photodynamic therapy and 3 consecutive intravitreal bevacizumab injections at 6-week intervals were given. Best corrected visual acuity, subretinal fluid (SRF), pigment epithelium detachment (PED), central macular thickness (CMT), and total macular volume (TMV) were measured before and after treatment as assessed by Stratus OCT3. RESULTS: After treatment, the SRF height decreased earlier than the PED height. The SRF diameter decreased with statistical significance. However, the PED diameter did not show a statistically significant improvement, persisting at pre-treatment levels. Both CMT and TMV decreased significantly after treatment. CONCLUSIONS: After PCV treatment, SRF and PED stabilized, as shown by OCT. However, the PED treatment response was both delayed and refractory compared to the SRF response. The small change in post-treatment PED diameter may suggest the possibility of PCV recurrence.
Aged
;
Choroid/*pathology
;
Choroid Diseases
;
Choroidal Neovascularization/diagnosis/*drug therapy
;
Disease Progression
;
Female
;
Fluorescein Angiography
;
Follow-Up Studies
;
Fundus Oculi
;
Humans
;
Male
;
Photochemotherapy/*adverse effects
;
Prognosis
;
Retinal Detachment/diagnosis/*etiology
;
Retinal Pigment Epithelium/*pathology
;
Retrospective Studies
;
*Subretinal Fluid
;
Time Factors
;
Tomography, Optical Coherence
;
Visual Acuity